Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;134(Pt 9):2627-41.
doi: 10.1093/brain/awr193.

Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis

Affiliations

Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis

Laura Ferraiuolo et al. Brain. 2011 Sep.

Abstract

Amyotrophic lateral sclerosis is a neurodegenerative disease in which death of motoneurons leads to progressive failure of the neuromuscular system resulting in death frequently within 2-3 years of symptom onset. Focal onset and propagation of the disease symptoms to contiguous motoneuron groups is a striking feature of the human disease progression. Recent work, using mutant superoxide dismutase 1 murine models and in vitro culture systems has indicated that astrocytes are likely to contribute to the propagation of motoneuron injury and disease progression. However, the basis of this astrocyte toxicity and/or failure of motoneuron support has remained uncertain. Using a combination of in vivo and in vitro model systems of superoxide dismutase 1-related amyotrophic lateral sclerosis, linked back to human biosamples, we set out to elucidate how astrocyte properties change in the presence of mutant superoxide dismutase 1 to contribute to motoneuron injury. Gene expression profiling of spinal cord astrocytes from presymptomatic transgenic mice expressing mutant superoxide dismutase 1 revealed two striking changes. First, there was evidence of metabolic dysregulation and, in particular, impairment of the astrocyte lactate efflux transporter, with resultant decrease of spinal cord lactate levels. Second, there was evidence of increased nerve growth factor production and dysregulation of the ratio of pro-nerve growth factor to mature nerve growth factor, favouring p75 receptor expression and activation by neighbouring motoneurons. Functional in vitro studies showed that astrocytes expressing mutant superoxide dismutase 1 are toxic to normal motoneurons. We provide evidence that reduced metabolic support from lactate release and activation of pro-nerve growth factor-p75 receptor signalling are key components of this toxicity. Preservation of motoneuron viability could be achieved by increasing lactate provision to motoneurons, depletion of increased pro-nerve growth factor levels or p75 receptor blockade. These findings are likely to be relevant to human amyotrophic lateral sclerosis, where we have demonstrated increased levels of pro-nerve growth factor in cerebrospinal fluid and increased expression of the p75 receptor by spinal motoneurons. Taken together, these data confirm that altered properties of astrocytes are likely to play a crucial role in the propagation of motoneuron injury in superoxide dismutase 1-related amyotrophic lateral sclerosis and indicate that manipulation of the energy supply to motoneurons as well as inhibition of p75 receptor signalling may represent valuable neuroprotective strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lactate levels were measured in spinal cord homogenates from SOD1G93A mice and NtgG93A at 30, 40 and 60 days of age (A) (n = 6 and bars = SD, two-tailed t-test) and in the culture media after growing astrocytes from SOD1G93A and SOD1WT and respective non-transgenic littermates (NtgG93A and NtgWT) in monoculture for 21 days (B) and in ‘separated co-cultures’ with non-transgenic motoneurons for 14 days (C) (n = 3, each n is a triplicate, and bars = SD). Results are expressed as percentage of the lactate released in the media by non-transgenic astrocytes.
Figure 2
Figure 2
Motoneuron survival after 14 days of co-culture with SOD1G93A (Tg) or NTg astrocytes (n = 3, each n is a triplicate, bars = SD, one-way ANOVA plus Tukey's multiple comparison test). Results were normalized to motoneuron survival grown on NTg astrocytes without lactate treatment. Statistical analysis was performed comparing all groups to motoneuron survival on SOD1G93A (significance = #; where ## = <0.01; ###= <0.001) or NTg (significance =*; where *= <0.05; **= <0.01) astrocytes under basal conditions. SOD1G93A astrocytes increase motoneuron death by 38% (**P < 0.01) compared with NTg astrocytes under basal conditions. The addition of 0.5 mM lactate has no effect, while 1 mM lactate completely rescues motoneuron viability on SOD1G93A astrocytes. Lactate (2 mM) concentration improves motoneuron survival on SOD1G93A astrocytes compared with motoneuron survival on NTg astrocytes untreated (**P < 0.01). NTg = non-transgenic; Tg = transgenic.
Figure 3
Figure 3
Ngf release in the media normalized to the levels found in astrocyte monocultures. SOD1G93A astrocytes release 70% more Ngf after being co-cultured with motoneurons (**P = 0.0016), and they release 38% more than NtgG93A (*P = 0.025), 33% more than SOD1WT (P = 0.022) and 43% more than NtgWT (P = 0.0035) in the same conditions (n = 3, each n is a triplicate, bars = SD, two-tailed t-test). MN = motoneuron.
Figure 4
Figure 4
Motoneuron survival after 14 days of co-culture with SOD1G93A (Tg) or NTg astrocytes under basal conditions, with Ngf depletion and with Ngf depletion combined with 1 mM lactate supplementation (n = 3, each n is a triplicate, bars = SD, one-way ANOVA). Results were normalized to motoneuron survival grown on NTg astrocytes under basal conditions. Statistical analysis was performed comparing all groups to motoneuron survival on SOD1G93A (significance = #, where #= < 0.05; ##= < 0.01) or NTg (significance =*, where *= < 0.05; ***= < 0.001) astrocytes under basal conditions. SOD1G93A astrocytes increase motoneuron death by 40% (P = 0.0004, two-tailed t-test) compared to NTg astrocytes under basal conditions. Ngf depletion partially rescues motoneuron viability on SOD1G93A astrocytes (20% increase, P<0.05), and, when combined with 1 mM lactate in the media, motoneuron survival is totally rescued. Motoneuron survival is significantly reduced by Ngf depletion in co-cultures with NTg astrocytes (40% increased death, P<0.001); lactate partially rescues motoneuron loss reducing motoneuron death by 15% (P < 0.05). NTg = non-transgenic; Tg = transgenic.
Figure 5
Figure 5
Western blot (A) and densitometry (B) of total Ngf immunoprecipitated from the media collected from SOD1G93A and Ntg astrocyte co-cultured with non-transgenic motoneurons for 14 days. Western blotting showed the presence of two forms of Ngf: pro-NGF (33 kDa), and mutant Ngf (13 kDa). Densitometry revealed that in the medium from co-cultures of SOD1G93A astrocytes with non-transgenic motoneurons the pro-NGF/mutant Ngf ratio is 2-fold higher (P = 0.001, two-tailed t-test) than in co-cultures with non-transgenic astrocytes (n = 6; error bar = SD). (B) Densitometry results for pro-NGF/NGF ratio when co-cultures are treated with lactate, p75 inhibitor and fgfr1 inhibitor (n = 3; error bar = SD, one-way ANOVA). Statistical analysis was performed comparing all groups to Ntg (significance =*, where *= < 0.05; **=<0.01) or SOD1G93A (significance = #, where #= <0.05. n.s. = not significant) Levels of pro-NGF/NGF were also analysed for Ntg co-cultures, but there was no significant difference between treatments (data not shown).
Figure 6
Figure 6
p75 expression in motoneuron cultured for 14 days on SOD1G93A or Ntg astrocytes under basal conditions (a and b), with 1mM lactate supplementation (c and d) and Ngf depletion (e and f). p75 fluorescence has been quantified and expressed as integrated density (g) in order to capture the quantity of p75 expressed and pixel/cell (h) in order to quantify the area positive for p75. Statistical analysis was performed comparing all groups to p75 expression in motoneurons grown on Ntg (significance =*, where *=<0.05; **= < 0.01; ***= < 0.001) or SOD1G93A astrocytes (significance = # where #= <0.05; ##= < 0.01; ###= < 0.001) under basal conditions (n = 60, bars = SD, one-way ANOVA). Our results show that motoneurons cultured under the influence of SOD1G93A astrocytes show expression of p75 within dendrites and axons as well as the perikarya (a), which is absent in all other conditions (bf). Consistently, fluorescence quantification (gh) shows that p75 intensity is significantly higher in normal motoneurons co-cultured for 14 days with SOD1G93A astrocytes compared to motoneurons co-cultured with Ntg astrocytes (P < 0.0001) and the area positive for p75 is significantly higher (P < 0.05). Both lactate supplementation and NGF depletion cause a significant reduction in the area positive for p75, bringing it to levels comparable to those observed in non-transgenic co-cultures. The intensity of p75, nevertheless, reaches normal levels in motoneurons cultured with transgenic astrocytes only after NGF depletion (P < 0.0001).
Figure 7
Figure 7
Motoneuron survival after 14 days of co-culture with Ntg or SOD1G93A astrocytes under basal conditions and with p75 inhibitory antibody addition to the media at 3 or 6 days after co-culture (n = 3, each n is a triplicate, bars = SD, one-way ANOVA). Results were normalized to motoneuron survival grown on Ntg astrocytes under basal conditions. Statistical analysis was performed comparing all groups to motoneuron survival on Ntg (significance =*) or SOD1G93A (significance = #) astrocytes under basal conditions. SOD1G93A astrocytes increase motoneuron death by 40% (**P = 0.0015, two-tailed t-test) compared to Ntg astrocytes under basal conditions. Motoneuron survival is totally rescued when the p75 inhibitory antibody is added at either 3 (##P < 0.01) or 6 days (#P < 0.05) after co-culture.
Figure 8
Figure 8
NGF quantification in CSF from non-neurological controls and patients with ALS using ELISA (A) for total NGF (pro-NGF + mutant NGF) and western blotting (B). The ELISA test (A) revealed that patients with ALS have CSF levels of NGF significantly higher than controls (P = 0.009; n = 13, error bar = SD, two-tailed t-test). Western blot analysis (B) of NGF immunoprecipitated from CSF showed that in samples where NGF levels were within the range of detection for western blotting (4–8 pg/ml), pro-NGF (33 kDa) is typically more abundant in CSF from patients with ALS than non-neurological controls (CTR). In contrast, NGF (13 kDa) is less abundant. This results in a ratio pro-NGF/NGF ∼40% higher in patients with ALS compared with controls.
Figure 9
Figure 9
Quantitative polymerase chain reaction to quantify the expression of p75 in motoneurons isolated from the spinal cord of control individuals and patients with ALS (n = 3 and bars = SD, two-tailed t-test). Results are expressed as relative concentrations (rel con) after normalization to Gapdh levels. p75 is significantly upregulated in motoneurons from patients with ALS (**P = 0.0018).

Similar articles

Cited by

References

    1. Bierl MA, Jones EE, Crutcher KA, Isaacson LG. ‘Mature’ nerve growth factor is a minor species in most peripheral tissues. Neurosci Lett. 2005;380:133–7. - PubMed
    1. Bilsland LG, Nirmalananthan N, Yip J, Greensmith L, Duchen MR. Expression of mutant SOD1 in astrocytes induces functional deficits in motoneuron mitochondria. J Neurochem. 2008;107:1271–83. - PubMed
    1. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–92. - PubMed
    1. Boyd JG, Gordon T. The neurotrophin receptors, trkB and p75, differentially regulate motor axonal regeneration. J Neurobiol. 2001;49:314–25. - PubMed
    1. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA. 2006;103:6735–40. - PMC - PubMed

Publication types

MeSH terms